PMID- 34383256
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 41
IP  - 9
DP  - 2021 Sep
TI  - Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
PG  - 829-834
LID - 10.1007/s40261-021-01069-8 [doi]
AB  - Moxetumomab pasudotox (Lumoxiti((R))), an anti-CD22 recombinant immunotoxin, is an 
      important treatment option that is approved in adults with relapsed or refractory 
      hairy cell leukaemia (HCL) who have received at least two prior lines of 
      treatment with systemic therapies including purine nucleoside analogues. In a 
      pivotal phase III trial, treatment with moxetumomab pasudotox resulted in 
      approximately one third of patients achieving durable complete response lasting 
      more than 6 months, as well as improvements in other haematological parameters 
      and disease-related symptoms. Moxetumomab pasudotox had a generally manageable 
      tolerability profile; the most common treatment-related adverse events (AEs) 
      included nausea, peripheral oedema, headache and pyrexia. AEs of special interest 
      (including haemolytic uraemic syndrome and capillary leak syndrome) were 
      generally manageable and reversible with monitoring and supportive care.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Kang, Connie
AU  - Kang C
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210812
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bacterial Toxins)
RN  - 0 (Exotoxins)
RN  - 2NDX4B6N8F (immunotoxin HA22)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Bacterial Toxins/therapeutic use
MH  - Exotoxins/therapeutic use
MH  - Humans
MH  - *Leukemia, Hairy Cell/diagnosis/drug therapy
OAB - HCL is a rare form of leukaemia ( approximately  2% of all leukaemia cases) that may cause 
      symptoms such as anaemia, easy bruising and recurrent infection due to the low 
      production of normal blood cells. Although treatment options are available, 
      options are limited in patients with HCL who have relapsed (disease has 
      reappeared after remission) or are refractory (does not respond) to treatment. 
      Moxetumomab pasudotox (Lumoxiti((R))) binds to a specific protein that is 
      overexpressed on the surface of malignant B cells, and is approved to treat 
      adults with relapsed or refractory HCL who have been treated at least twice with 
      systemic therapies, including a purine nucleoside analogue, for HCL. In 
      approximately one third of patients treated with moxetumomab pasudotox, no HCL 
      cells were found in blood or bone marrow for at least 6 months; disease-related 
      symptoms were also improved. Moxetumomab pasudotox had a generally manageable 
      adverse event profile. While infrequent, serious adverse events such as 
      haemolytic uraemic syndrome and capillary leak syndrome can occur, and are 
      generally manageable and reversible with monitoring and supportive medical care 
      (e.g. adequate oral hydration). Thus, moxetumomab pasudotox is an important 
      treatment option in patients with relapsed or refractory HCL who have received at 
      least two previous treatments for HCL.
OABL- eng
EDAT- 2021/08/13 06:00
MHDA- 2021/09/01 06:00
CRDT- 2021/08/12 12:34
PHST- 2021/07/25 00:00 [accepted]
PHST- 2021/08/13 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/08/12 12:34 [entrez]
AID - 10.1007/s40261-021-01069-8 [pii]
AID - 10.1007/s40261-021-01069-8 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2021 Sep;41(9):829-834. doi: 10.1007/s40261-021-01069-8. Epub 
      2021 Aug 12.